newsfilter
← Latest News
GlobeNewswire·

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral